Health Economics and Outcomes Research

A 21-gene assay poses an overall incremental cost increase to the health care system in the short-term, despite lower rates of chemotherapy use.
Although the ASCO Value Framework can help quantify the health value and benefit of various cancer therapies, it has essential limitations for its use in the treatment of chronic lymphocytic leukemia.
A recent study found that the generic version of capecitabine has yielded less cost savings over a 3-year span than expected, which is likely a reflection of the lack of generic manufacturers entering the market.
A multikinase inhibitor used in the second-line setting for hepatocellular carcinoma offers limited increases in quality-adjusted life years.
A long-term post-hoc analysis compared the effects of three therapy regimens for the initial treatment of patients with a type of advanced-stage B-cell malignancy.
A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications.
Researchers have identified follow-up care and outcomes disparities for patients with brain metastasis treated with stereotactic radiosurgery in a private hospital compared with those treated in a safety-net hospital.
A recent study investigated the drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.
The percentage of US adults under age 65 who skip essential prescription drugs because of price has declined, a five-year study found. But consistently, problems with financial access to medication were more common in cancer survivors.
Chemotherapy drug waste from single-dose vials increased 3-year incremental budget costs by over $100 million in Canada, but is not being modeled uniformly in economic evaluations.